# BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer

> **NCT00708214** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 28 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** BIBW 2992
- **DRUG:** BIBW 2992
- **DRUG:** Letrozole
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT00708214
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2010-02
- **Final completion:** —
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2013-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00708214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00708214, "BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00708214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*